Korro Bio (NASDAQ:KRRO) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Korro Bio (NASDAQ:KRRO – Free Report) in a report published on Friday, Benzinga reports. The brokerage currently has a $100.00 price objective on the stock. A number of other brokerages also recently issued reports on KRRO. Royal Bank of Canada assumed coverage on Korro Bio in […]

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Canada ,Massachusetts ,United States ,Korro Bio ,Davidl Lucchino ,Piper Sandler ,Nasdaq ,Star Investment Management Corp ,Royal Bank ,Korro Bio Inc ,Securities Exchange Commission ,Free Report ,Director David ,Exchange Commission ,Star Investment Management ,Get Free Report ,Korro Bio Daily ,Nasdaq Krro ,Krro ,Medical ,Reiterated Rating ,Hc Wainwright ,